Kamu erişimi zorunlu olan makaleler - Daniel Y C HengDaha fazla bilgi edinin
Hiçbir yerde sunulmuyor: 5
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma
DYC Heng, RM Bukowski
Current cancer drug targets 8 (8), 676-682, 2008
Zorunlu olanlar: Canadian Institutes of Health Research
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival …
E Bria, F Massari, F Maines, S Pilotto, M Bonomi, C Porta, S Bracarda, ...
Critical Reviews in Oncology/Hematology 93 (1), 50-59, 2015
Zorunlu olanlar: Government of Italy
Cost-utility of sunitinib versus pazopanib in metastatic renal cell carcinoma in Canada using real-world evidence
S Nazha, S Tanguay, A Kapoor, M Jewett, C Kollmannsberger, L Wood, ...
Clinical drug investigation 38, 1155-1165, 2018
Zorunlu olanlar: Fonds de recherche du Québec - Santé
Real-world assessment of clinical outcomes in patients with metastatic renal cell carcinoma with or without sarcomatoid features treated with first-line systemic therapies
GBN Sawaya, A Dragomir, LA Wood, C Kollmannsberger, NS Basappa, ...
European Urology Oncology 7 (3), 570-580, 2024
Zorunlu olanlar: Fonds de recherche du Québec - Santé
Combination therapy in metastatic renal cell carcinoma.
M Sun, F Abdollah, SF Shariat, R Thuret, C Jeldres, P Perrotte, ...
Current Medical Literature: Kidney Cancer 2 (4), 2010
Zorunlu olanlar: Fonds de recherche du Québec - Santé
Bir yerde sunuluyor: 69
Renal cell carcinoma
JJ Hsieh, MP Purdue, S Signoretti, C Swanton, L Albiges, M Schmidinger, ...
Nature reviews Disease primers 3 (1), 1-19, 2017
Zorunlu olanlar: US National Institutes of Health, National Institute for Health Research, UK
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
Zorunlu olanlar: US National Institutes of Health
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
Zorunlu olanlar: US National Institutes of Health
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised …
RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ...
The Lancet Oncology 20 (10), 1370-1385, 2019
Zorunlu olanlar: US National Institutes of Health
Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study
HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ...
Journal of Clinical Oncology 35 (34), 3851-3858, 2017
Zorunlu olanlar: US National Institutes of Health
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first …
JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ...
The lancet oncology 16 (3), 293-300, 2015
Zorunlu olanlar: US National Institutes of Health, Canadian Institutes of Health Research
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
RR McKay, N Kroeger, W Xie, JL Lee, JJ Knox, GA Bjarnason, ...
European urology 65 (3), 577-584, 2014
Zorunlu olanlar: US National Institutes of Health
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database …
N Kroeger, W Xie, JL Lee, GA Bjarnason, JJ Knox, MJ MacKenzie, ...
Cancer 119 (16), 2999-3006, 2013
Zorunlu olanlar: US National Institutes of Health
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
SK Pal, C Tangen, IM Thompson, N Balzer-Haas, DJ George, DYC Heng, ...
The Lancet 397 (10275), 695-703, 2021
Zorunlu olanlar: US National Institutes of Health
Body mass index and metastatic renal cell carcinoma: clinical and biological correlations
L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov, X Lin, JL Lee, ...
Journal of Clinical Oncology 34 (30), 3655-3663, 2016
Zorunlu olanlar: US National Institutes of Health
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma
DJ Kwiatkowski, TK Choueiri, AP Fay, BI Rini, AR Thorner, G De Velasco, ...
Clinical Cancer Research 22 (10), 2445-2452, 2016
Zorunlu olanlar: US National Institutes of Health
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group
J Manola, P Royston, P Elson, JB McCormack, M Mazumdar, S Négrier, ...
Clinical Cancer Research 17 (16), 5443-5450, 2011
Zorunlu olanlar: US National Institutes of Health, Cancer Research UK
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
A Amin, ER Plimack, MS Ernstoff, LD Lewis, TM Bauer, DF McDermott, ...
Journal for immunotherapy of cancer 6, 1-12, 2018
Zorunlu olanlar: US National Institutes of Health
Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium
S Gillessen, N Sauvé, L Collette, G Daugaard, R de Wit, C Albany, ...
Journal of Clinical Oncology 39 (14), 1563-1574, 2021
Zorunlu olanlar: US National Institutes of Health, UK Medical Research Council, Swiss Cancer …
Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11. 2 translocation renal cell carcinoma
TK Choueiri, ZD Lim, MS Hirsch, P Tamboli, E Jonasch, DF McDermott, ...
Cancer 116 (22), 5219-5225, 2010
Zorunlu olanlar: US National Institutes of Health
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir